Cerebral palsy, ataxic, autosomal recessive

Summary

Cerebral palsy, ataxic, autosomal recessive (MONDO:0011548) is a disease and 6 clinical trials. Top therapeutic interventions include leucine. A subtype of ataxic cerebral palsy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cerebral palsy, ataxic, autosomal recessive
Mondo ID	MONDO:0011548
OMIM	605388
GARD	0010451
Is cancer (heuristic)	no

Also known as: ataxic cerebral palsy · cerebral palsy ataxic · cerebral palsy, ataxic, autosomal recessive

Disease family

This is a subtype of ataxic cerebral palsy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › palsy › cerebral palsy › ataxic cerebral palsy › cerebral palsy, ataxic, autosomal recessive

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	6

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05227066	Not specified	ACTIVE_NOT_RECRUITING	Efficacy of Adding Lower Extremity Weights on Balance in Children With Ataxic Cerebral Palsy
NCT06639802	Not specified	RECRUITING	Effects of Hand Arm Bimanual Intensive Therapy Including Lower Extremity on Balance and Coordination in Ataxic Cerebral Palsy
NCT07291128	Not specified	RECRUITING	Effects of VOJTA Technique on Ataxic Cerebral Palsy.
NCT07421219	Not specified	NOT_YET_RECRUITING	ARTEMIS - The ARTEMIS Cohort
NCT03668548	Not specified	UNKNOWN	10-week Leucine Supplementation in Cerebral Palsy
NCT05411328	Not specified	COMPLETED	Efficacy of Virtual Reality on Balance in Children With Ataxic Cerebral Palsy Randomized Controlled Trail

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LEUCINE	3	1